This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …

This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …

At present, there are some differences in the research results of nirmatrelvir–ritonavir
compared with other antiviral drugs for the treatment of COVID‐19 patients. We aimed to …

The landscape of development of treatment modalities and preventive measures for COVID-
19 has progressed expeditiously since the beginning of the pandemic. We included all the …

Despite the need for novel, effective therapeutics for the COVID-19 pandemic, no curative
regimen is yet available, therefore patients are forced to rely on supportive and nonspecific …

Background Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …

Objective Provide a timely, rigorous, and continuously updated summary of the evidence on
the role of lopinavir/ritonavir in the treatment of patients with COVID-19. Methods We …

(Background) Lopinavir-ritonavir (LPV/RTV) is a human immunodeficiency virus (HIV)
antiviral combination that has been considered for the treatment of COVID-19 disease.(Aim) …

Background Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID-
19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure …

Nirmatrelvir/ritonavir (Paxlovid™) is an effective and safe antiviral drug that inhibits the main
protease (Mpro), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related …